SCHEMBL6545127

SCHEMBL6545127

CCCC(CCc1cc(OC)ccc1C=CC(=O)O)CCc1ccccc1C(=O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 3/20 0.44
PTGER4 P35408 2/20 0.44
PTGER2 P43116 2/20 0.44
ALDH1A1 P00352 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
PGR P06401 1/20 0.41
CYP2D6 P10635 1/20 0.41
HPGD P15428 1/20 0.41
SLC6A2 P23975 1/20 0.41
PDE4A P27815 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HRH1 P35367 1/20 0.41
HTT P42858 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8916962 0.84 ALDH1A1 (0.39) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL27931915 0.79 NPC1 (0.43) RAB9ANPC1MAPTKMT2A
SCHEMBL489472 0.77 PTGER4 (0.51) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL489473 0.77 PTGER4 (0.51) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL290383 0.76 PTGER4 (0.48) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL196086 0.76 PTGER4 (0.48) PTGER3PTGER4PTGER2ALDH1A1RAB9A
Cinnamic Acid SCHEMBL20555429 0.75 PTGER4 (0.57) PTGER3PTGER4PTGER2ALDH1A1RAB9A
Cinnamic Acid SCHEMBL20555426 0.75 PTGER4 (0.57) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL5178122 0.74 PTGER4 (0.49) PTGER3PTGER4PTGER2ALDH1A1RAB9A
SCHEMBL6367849 0.74 PTGER4 (0.49) PTGER3PTGER4PTGER2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713075-B2 BONDING AGENT SELECTED FROM ALDEHYDES AND KETONES, AND A COSMETICALLY ACCEPTABLE CARRIER FOR BONDING AGENT WHEN ADMINISTERED TOPICALLY TO MAMMALS PROTEINACEOUS SUBSTRATE BONDING AGENT REACTS WITH PROTEIN FORMING A COVALENT BOND THE PROCTER & GAMBLE COMPANY 2004-03-30 US disclosed
EP-1392235-A2 TOPICAL COMPOSITION COMPRISING AN ACTIVATED, TRANS-STRUCTURED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-03-03 EP disclosed
EP-1392236-A2 TOPICAL COSMETIC COMPOSITION COMPRISING AN ALPHA-BETA-UNSATURATED ESTER AS BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-03-03 EP disclosed
EP-1379216-A2 TOPICAL COMPOSITION COMPRISING A DIAZONIUM SALT-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-01-14 EP disclosed
EP-1379218-A2 TOPICAL COMPOSITION COMPRISING A FUNCTIONAL AROMATIC DERIVATIVE COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-01-14 EP disclosed
EP-1377272-A2 TOPICAL COMPOSITION COMPRISING A 1, 2-HETEROATOM CONSTITUTED DIENE COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-01-07 EP disclosed
EP-1377270-A2 TOPICAL COMPOSITION COMPRISING A THREE MEMBERED CYCLIC COMPOUND-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2004-01-07 EP disclosed
EP-1370234-A2 TOPICAL COMPOSITION COMPRISING A CYCLIC IMIDOCARBONATE-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2003-12-17 EP disclosed
EP-1370235-A2 TOPICAL COMPOSITION COMPRISING AN ALDEHYDE OR KETONE-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2003-12-17 EP disclosed
EP-1367992-A2 TOPICAL COMPOSITION COMPRISING A FUNCTIONALLY ALKYLATING COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2003-12-10 EP disclosed
US-20020172701-A1 Topical composition comprising a functionalized acid anhydride-based cosmetic bonding agent PROCTER & GAMBLE COMPANY, THE 2002-11-21 US disclosed
WO-2002076414-A2 COSMETIC TOPICAL COMPOSITION COMPRISING A FUNCTIONAL AROMATIC DERIVATIVE BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-10-03 WO disclosed
WO-2002072056-A2 TOPICAL COMPOSITION COMPRISING A DIAZONIUM SALT-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072043-A2 TOPICAL COMPOSITION COMPRISING A 1, 2-HETEROATOM CONSTITUTED DIENE COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072058-A2 TOPICAL COMPOSITION COMPRISING A FUNCTIONALIZED ACID ANHYDRIDE-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072061-A2 TOPICAL COMPOSITION COMPRISING AN ALDEHYDE OR KETONE-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072059-A2 TOPICAL COMPOSITION COMPRISING A FUNCTIONALLY ALKYLATING COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072057-A2 TOPICAL COMPOSITION COMPRISING A FUNCTIONALLY ACYLATING COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072060-A2 TOPICAL COMPOSITION COMPRISING A THREE MEMBERED CYCLIC COMPOUND-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed
WO-2002072055-A2 TOPICAL COMPOSITION COMPRISING A CYCLIC IMIDOCARBONATE-BASED COSMETIC BONDING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020172701-A1 Topical composition comprising a functionalized acid anhydride-based cosmetic bonding agent CUTA, CRYAA, ASAH1 PTGER3 4763/4885PTGER4 4664/4885PTGER2 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.